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Table 1 – Checklist used for critical analysis of the
evidence.
Study details
References, study design,
Jadad score, strength of
evidence
Sample calculation
Estimated differences,
power, level of significance,
total patients
Patient selection
Inclusion and exclusion
criteria
Patients
Recruited, randomized,
prognostic differences
Randomization
Description and blinded
allocation
Patient follow up
Time, lost to study
Treatment plan
Intervention, control and
blinding
Analysis
Treatment intervention,
analyzed and control
Outcomes considered
Primary, secondary,
instrument to measure the
Result
Benefit or harm in absolute
data. Mean benefit or harm
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Evidence  selected  in  the  critical  evaluationoutcome of interest
escription  of  the  evidence  collection  method
he members of the ABHH Committee responsible for writ-
ng the guidelines on the treatment of anemia of chronic renal
ailure using recombinant human erythropoietin prepared the
ain question related to its treatment. The issue was struc-
ured using the Patient/Problem, Intervention, Comparison
nd Outcome (PICO) system. The search strategy (Appendix
) was applied to the primary scientific databases (MEDLINE
ubMed, Embase, SciELO and, Lilacs) and secondary scientific
atabase (Cochrane Library).
Methodological quality was assessed using the Jadad
core,1 but this was not used as an exclusion criterion. The
ritical assessment of the studies considered items with Jadad
cores < 3 as inconsistent, and those with scores ≥ 3 consis-
ent. The strength of evidence was analyzed according to the
xford classification.2
ecommendation  degree  and  evidence  level  (Oxford
lassification)
A: Experimental or observational studies of better consis-
tency
B: Experimental or observational studies with less consis-
tency
C: Case reports (uncontrolled studies)
D: Opinion without critical evaluation based on consensus,
physiological studies or animal models
ackground
sually identified when the glomerular filtration rate falls
elow 30 mL/min, normocytic normochromic anemia is
resent in most patients with chronic kidney disease.
lthough this type of anemia has many  causes, it is mainly
elated to reduced production of erythropoietin, a glycopro-
ein hormone of 165 amino acids with a molecular weight of
0.4 kDa, responsible for the regulation of erythropoiesis and
ubsequent maintenance of oxygen homeostasis.3 1 4;3  6(6):450–453 451
Erythropoietin is a hematopoietic growth factor primarily
produced in the kidney cortex, which stimulates the prolifer-
ation and differentiation of erythroid progenitor cells in the
bone marrow; when erythropoietin is absent these progen-
itor cells are not protected against apoptosis. Patients with
chronic kidney disease gradually develop an inability to pro-
duce adequate amounts of erythropoietin to maintain normal
hemoglobin levels.4
Recombinant human erythropoietin (epoetin alfa and epo-
etin beta) was produced to meet the needs of these patients
by culturing transformed cells from Chinese hamster ovaries
and the kidneys of young hamsters. With a half-life of 24 h,
epoetin carries complementary DNA that encodes human
erythropoietin.4
The short half-life of epoetin with the necessity of frequent
doses, led the pharmaceutical industry to investigate strate-
gies to prolong the action of the molecule. This resulted in
the development of darbepoetin alfa with a half-life of 72 h,
and continuous erythropoietin receptor activator (CERA) with
a half-life of around 130 h.4
Aims
To evaluate the benefits and adverse effects of recombinant
human erythropoietin and CERA to treat anemia in dialysis
and predialysis kidney disease patients.
Search  question
What are the main benefits and adverse effects of recombi-
nant erythropoietin, darbepoetin alfa and CERA used to treat
anemia in dialysis and predialysis kidney disease patients?
Studies  selection  inclusion  criteria
All full text clinical randomized controlled trials produced
between 1981 and 2014 in Portuguese, English and Spanish
were considered for the creation of these guidelines.
The type II error was not used in the selection of studies so
as not to impose an even greater limitation on the selection.
According to the PICO system, all patients with chronic
renal failure and anemia in dialysis or pre-dialysis were
included without age restriction. Interventions included
treatment with erythropoietin, CERA or darbepoetin alfa.
Conventional treatment and placebo were compared and
outcomes were defined with an assessment of therapeutic
response, such as the level of hemoglobin and the need for
transfusion.
A total of 411 studies were chosen for analysis (PubMed-
Medline: 396; Embase: 13 and Scielo/Lilacs and Cochrane via
the Biblioteca Virtual en Salud: 2). A total of 352 articles were
selected after the first analysis, all were from the primary
electronic databases with no other articles being found in a
manual search.The papers were critically evaluated in respect to the inclu-
sion and exclusion criteria and 342 papers were excluded
oter.
Adverse  effects
Treatment with darbepoetin alfa increases the incidence of452  rev bras hematol hem
leaving ten articles to comprise the guidelines. No article was
excluded due to the unavailability of the full text. Table 1 was
used in the critical analysis of the articles.
Erythropoietin
Stage 5 renal failure patients in chronic peritoneal dialysis
with anemia (hematocrit <30%) who received erythropoi-
etin (4000 U three times weekly if hematocrit was <32%, and
two times weekly if hematocrit was between 32% and 38%)
have improvements in anemia after six to 12 weeks of treat-
ment (number needed to treat [NNT] = 2) when compared to a
placebo. There is no increase in the incidence or the severity of
adverse events related to the drug. Patients in treatment may
have a worsening of blood pressure control (number needed
to harm [NNH] = 3)5 (A).
Anemic patients with pre-dialysis chronic renal failure
receiving erythropoietin (50–150 U/kg three times a week) have
a better therapeutic response (6% increase in hematocrit from
baseline) compared to placebo (NNT = 2). There is no increase
in the incidence of adverse events such as high blood pres-
sure, headache, joint pain, swelling, and discontinuation of
treatment6 (A).
Anemic patients (hemoglobin <9 g/dL) on hemodialysis
receiving erythropoietin have reduced need for transfusion
(NNT = 2), and an elevated risk of increases in diastolic pres-
sure with the need for antihypertensive drugs (NNH = 6)7–9 (A).
Darbepoetin  alfa
In adult patients with chronic renal failure (creatinine
>4 mg/dL and creatinine clearance <30 mL/min per 1.73 m2)
and anemia (hematocrit <30%), treatment with darbepo-
etin alfa at a dose of 0.45 mg/kg subcutaneously, once every
two weeks, or treatment with erythropoietin alfa at a dose
90 IU/kg subcutaneously, once per week, compared to treat-
ment without drugs that modify the biological course of
disease results in an average 30% increase in the concentration
of hemoglobin and improvements in left ventricular ejection
fraction, although there is no improvement in renal function10
(B).
On comparing adult patients on peritoneal dialysis for at
least three months with hemoglobin levels between 8 and
12 g/dL under treatment with recombinant erythropoietin to
those treated with darbepoetin alfa at a dose of 0.45 mg/kg sub-
cutaneously once every two weeks, the latter group required
fewer doses to achieve the same increases in hemoglobin at
24 weeks of follow-up. The most common adverse events are
edema and iron deficiency11 (B).
Treatment of diabetic patients with chronic renal insuffi-
ciency (glomerular filtration rate 20–60 mL/min per 1.73 m2)
and anemia (hemoglobin level < 11 g/dL) using darbepoetin
alfa, results in significant increases in hemoglobin levels (20%
on average) within 24 months. There was a 9.7% reduction
in the number of transfusions (NNT = 10), but a 2.4% increase
in the occurrence of strokes (NNH = 40). There were no sig-
nificant differences in mortality or worsening renal function
among patients undergoing and not undergoing treatment
with darbepoetin alfa. The treatment increases arterial and
venous thromboembolic events by 0.9% (NNH = 100) and 1.8% 2 0 1 4;3  6(6):450–453
(NNH = 55), respectively. In patients with a history of cancer,
there is an increase in disease-related mortality12 (A).
Moreover, there is a 4% increase in cardiovascular events
(NNH = 25) and 2.4% increase in mortality (NNH = 40) in
patients with minor responses (increase of less than 2% in
hemoglobin levels in the first month of treatment)13 (A).
Continuous  erythropoietin  receptor  activator  (CERA)
In adult patients with chronic renal failure and anemia on
hemodialysis or peritoneal dialysis, the use of CERA (dose
between 60 and 180 mg  for two weeks) compared to treat-
ment with darbepoetin, produces no difference in benefits or
adverse events14 (A).
Closing  remarks
Recombinant human erythropoietin has been produced for
a long time to improve erythropoiesis, or red blood cell pro-
duction in patients with chronic renal failure. Synthetic forms
with longer half-lives have been developed successfully with
resulting improvements in anemia, quality of life and need
for transfusion, and time between applications. Hemoglobin
levels should be kept between 11 and 12 g/dL to avoid pos-
sible increases in cardiovascular events and thromboembolic
phenomena15 (A).
Summary  of  the  evidence
The  use  of  erythropoietin  to  treat  anemia  associated  to
chronic  renal  failure
Benefit
Treatment with erythropoietin increases hemoglobin levels
and reduces the number of transfusions needed.
Adverse  effects
Treatment with erythropoietin increases blood pressure, in
particular diastolic pressure, and the need of antihypertensive
drugs.
The  use  of  darbepoetin  alfa  to  treat  anemia  associated  to
chronic  renal  failure
Benefit
Treatment with darbepoetin alfa increases hemoglobin levels,
and reduces the number of doses of medication to obtain the
same level of hemoglobin compared to erythropoietin, thereby
reducing the number of transfusions. It improves the left ven-
tricular ejection fraction.stroke, increases venous and arterial thromboembolic events,
increases cancer-related mortality in patients with a history
of cancer, and increases mortality and cardiovascular events
in patients with poor response.
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he  use  of  continuous  erythropoietin  receptor  activator  to
reat anemia  associated  to  chronic  renal  failure
n patients with chronic renal insufficiency and anemia, there
re no significant differences in benefits or adverse effects
omparing the use of continuous erythropoietin receptor acti-
ator to treatment with darbepoetin.
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